|
|
 |
|
Viewing report
|
|
|
|
Opportunities and Challenges for Generic Drugs in the UK 2007
Espicom Business Intelligence Ltd, June 2007, Pages: 160
The £2.4 billion UK generics market is one of the world's largest in terms of both size and generic penetration. In 2005 over 59% of prescriptions were dispensed as generics, accounting for 26% of the market value. But fierce competition and price pressure are turning up the heat. How will the market continue to grow?
Key areas addressed:
-5-Year market forecast to 2012 for value
-The generics market in context of the whole pharmaceutical industry
-Pricing issues and reimbursement
-Political, legal and economic assessment
-Insightful review of 18 major domestic and foreign players in the market
-Detailed listing of 18 leading products including prescription data, price comparisons and marketing authorisations
Focus on developing generic markets for statins and proton pump inhibitors The UK generics market has proved a difficult operating environment in recent years. Many established suppliers have experienced declining sales and profitability, due to a number of factors. On the one hand, the market is relatively easy to enter, leading to rapid and fierce price competition for major drugs. On the other, the UK government keeps a close watch on generic drug pricing, and has proved willing to reduce prices for a number of products in recent years.
As in the wider global market, there are signs of ongoing industry consolidation. Teva and IVAX both have a strong presence in the UK, making Teva the clear market leader since its 2006 purchase of IVAX. One new development is the growing arrival of US companies in the market with control of Pliva going to Barr Laboratories in 2006, and Generics (UK) set to become part of Mylan in 2007. There are no major UK-owned generic manufacturers.
But who are the leading players and what are their strengths? What barriers to market entry exist? What marketing authorisations have recently been issued, and to whom? What will be the operating and regulatory environment for companies? The answers to these and many other questions can be found in this 160-page management report Opportunities and Challenges for Generic Drugs in the UK.
Customers who bought this item also bought
The World Generic Market Report 2008
Pliva Generics Company Intelligence Report
UK Pharmaceuticals and Healthcare Report Q3 2007
Pharmavitae Generics - Teva
Actavis Generics Company Intelligence Report
Global Generics Industry Report
Generic Pharmaceuticals Business Intelligence Report
Fire Security UK
Emerging Generic Drug Markets in Europe
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Ranbaxy Generics Company Intelligence Report
Sandoz - PharmaVitae Generics Profile
|
|
|
|
